Literature DB >> 23236003

Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation.

Virginia Conde1, Francisco J Palomar, María José Lama, Raquel Martínez, Fátima Carrillo, Elizabeth Pintado, Pablo Mir.   

Abstract

The fragile X syndrome is a mutation-driven developmental disorder caused by a repetition over 200 times of the CGG trinucleotide situated in the 5'-untranslated region of the fragile X mental retardation 1 gene (FMR1). The interval between 55 and 199 CGG repeats, which is over the normal range but below full mutation, is named fragile X premutation. Recent studies have focused on the asymptomatic state of fragile X premutation carriers and their potentially relevant preclinical features. However, the underlying neurological mechanisms leading to altered functions in fragile X premutation carriers are still poorly understood. In this study, we wanted to test the hypothesis that asymptomatic women who carry the fragile X premutation present GABAergic and cerebellar abnormalities compared with healthy women without the premutation. We performed noninvasive brain stimulation protocols on both asymptomatic fragile X premutation carriers and controls comprising of measures of GABAA- and GABAB-mediated intracortical inhibition, afferent inhibition, and cerebello-motor functional interactions. Premutation carriers presented an absence of cerebellar inhibition over primary motor cortex as well as a reduced GABAA-mediated intracortical and afferent inhibition compared with healthy nonpremutated controls. These alterations are most probably dependent on a dysfunctional GABAergic mechanism associated with the fragile X premutation condition as previously found in CGG-repeat animal models. Furthermore, the lack of cerebello-motor inhibition could be related to the cerebellar structural abnormalities previously found in carriers of the premutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23236003     DOI: 10.1152/jn.00730.2012

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  14 in total

Review 1.  Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications.

Authors:  Ramkumar Aishworiya; Dragana Protic; Randi Hagerman
Journal:  J Neurol       Date:  2022-06-20       Impact factor: 6.682

2.  Abnormal semantic processing in females with fragile X-associated tremor/ataxia syndrome.

Authors:  J-C Yang; C Simon; A Schneider; A L Seritan; L Hamilton; P J Hagerman; R J Hagerman; J M Olichney
Journal:  Genes Brain Behav       Date:  2013-12-26       Impact factor: 3.449

3.  Prevalence and risk of migraine headaches in adult fragile X premutation carriers.

Authors:  J Au; R S Akins; L Berkowitz-Sutherland; H-T Tang; Y Chen; A Boyd; F Tassone; D V Nguyen; R Hagerman
Journal:  Clin Genet       Date:  2013-02-21       Impact factor: 4.438

Review 4.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

Review 5.  Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers.

Authors:  Deborah A Hall; Erin Robertson; Annie L Shelton; Molly C Losh; Montserrat Mila; Esther Granell Moreno; Beatriz Gomez-Anson; Verónica Martínez-Cerdeño; Jim Grigsby; Reymundo Lozano; Randi Hagerman; Lorena Santa Maria; Elizabeth Berry-Kravis; Joan A O'Keefe
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

6.  Fragile X- associated Neuropsychiatric Disorders: A Case Report.

Authors:  Maria Melinda Tan; Jeanne Barbara Dy; Maria Jimena Salcedo-Arellano; Flora Tassone; Randi J Hagerman
Journal:  Future Neurol       Date:  2019-05-24

7.  Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study.

Authors:  Eleonora Napoli; Andrea Schneider; Jun Yi Wang; Aditi Trivedi; Nika Roa Carrillo; Flora Tassone; Michael Rogawski; Randi J Hagerman; Cecilia Giulivi
Journal:  Mol Neurobiol       Date:  2018-09-05       Impact factor: 5.590

8.  Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Authors:  Jonathan Polussa; Andrea Schneider; Randi Hagerman
Journal:  Brain Disord Ther       Date:  2014

Review 9.  Modulation of the GABAergic pathway for the treatment of fragile X syndrome.

Authors:  Reymundo Lozano; Emma B Hare; Randi J Hagerman
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-16       Impact factor: 2.570

Review 10.  The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome.

Authors:  Christian A Cea-Del Rio; Molly M Huntsman
Journal:  Front Cell Neurosci       Date:  2014-08-25       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.